---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-118284"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:21:56.766716+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix Q3 net loss $36.5M; SOL-1 topline data expected Q4 2025

## Summary
- Net loss of $36.5M ($0.22 diluted EPS) vs $0.5M loss in Q3 2023; R&D spend jumped to $37.1M.
- Total net revenue $15.4M (+2.3% YoY); DEXTENZA full-year 2024 revenue guided $62-67M.
- Cash $427.2M as of Sep 30, 2024, expected to fund operations into 2028.
- SOL-1 fully randomized by YE 2024 (accelerated); topline data now expected Q4 2025.
- SOL-R trial open for direct enrollment after FDA Type C response; NDA support confirmed.

## SEC filing metadata
- accession: 0001104659-24-118284
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465924118284/0001104659-24-118284-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465924118284/tm2428320d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-118284
- JSON: https://secwatch.observer/filing/0001104659-24-118284.json
- Plain text: https://secwatch.observer/filing/0001104659-24-118284.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.